FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number: 3235-02											
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) 3545 JOE	Street) SAN DIEGO CA 92121				2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE] 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)								6 Li	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) President and CEO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
				Fransac te onth/Da	ction 2A. Deemed Execution Date, if any (Month/Day/Yea		3. Tran Code 8)	sactio e (Instr	4. Secur Dispose 5) Amount	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5) Amount (A) or (D) Osed of, or Benefici			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	, 4. Tra	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Date (Month/Day/Yea		isable and te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		nt 8. De Se	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	de V		(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoun or Numbe of Shares	r					
Employee Stock Option (right to buy)	\$5.52	02/03/2022		A	A		83,000		(1)		02/03/2032	Common Stock	83,00	0	\$0.00	83,000)	D	
Restricted Stock Units	(2)	02/03/2022		A	\		41,500		(3)		(3)	Common Stock	41,50	0	\$0.00	41,500)	D	

Explanation of Responses:

- 1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
- $2. \ Each \ restricted \ stock \ unit \ (RSU) \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ common \ stock.$
- 3. The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Remarks:

Nancy E. Denyes, attorney-in-

02/07/2022

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.